Migraine
Conditions
Brief summary
Despite the fact that migraine is a common disorder, the pathogenesis is still not fully elucidated. Studying transcriptomic and biochemical changes during induced and spontaneous migraine-attacks will enhance our understanding and may point to new targets for drug development.
Detailed description
Migraine is a common neurological disorder affecting approx. 16 % of the European population. Despite the fact that migraine is a common disorder, the pathogenesis is still not sufficiently known. Studying transcriptomic and biochemical changes during spontaneous migraine-attacks will greatly enhance our understanding of migraine mechanisms and may point to new targets for drug development. Two blood samples (one for RNA analysis and one for biochemical analysis) are taken on minimum 15 patient with migraine with aura and 15 patients with migraine without aura when they experience a spontaneous migraine attack. A second sample is taken 2 hours after treatment with subcutaneous sumatriptan. Another two blood samples are taken when the patient has been migraine free for at least 5 days and had no other headache for at least 24 hours. A fourth set of blood samples are collected after a cold pressor test.
Interventions
OTHERBlood samples
There is no intervention, but we will take blood samples during a spontaneous migraine attack
Sponsors
Danish Headache Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Migraine patients who meet IHS criteria for migraine with or without aura of both sexes, * 18-70 years, * 45-95 kg.
Exclusion criteria
* any other type of headache then migraine without aura (except episodic tension-type headache \< 1 day per week), * serious somatic or psychiatric disease, * pregnancy, * and intake of daily medication (except oral contraceptives).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptomic changes | 2 year | The investigators will measure transcriptomic changes using Next Generation Sequencing during a migraine attack |
| Changes in CGRP levels during a migraine attack (CGRP1-37, CGRP1-17, CGRP18-37, CGRP1-26, CGRP27-37) | 2 year | The investigators will use advanced mass spectrometry to measure CGRP levels |
| Changes in PACAP levels during a migraine attack (PACAP-27, PACAP-38 ) | 2 years | The investigators will use advanced mass spectrometry to measure PACAP levels |
| Changes in VIP, glutamate, serotonin, PGE-2, nitric oxide metabolites, cAMP, and cGMP | 2 years | The investigators will use advanced mass spectrometry to measure VIP, glutamate, serotonin, PGE-2, nitric oxide metabolites, cAMP, and cGMP during a migraine attack |
| Changes in Metabolomics | 3 years | The investigators will use advanced mass spectrometry (LC-MS) to measure metabolomics in the 4 blood samples |
| Changes in Proteomics | 3 years | The investigators will use advanced mass spectrometry to measure proteomics in the 4 blood samples |
Countries
Denmark
Outcome results
None listed